The Inhibitors Of Tyrosine Kinase [os Inibidores De Tirosino Quinase De Segunda Geração]

dc.creatorDelamain M.T.
dc.creatorConchon M.
dc.date2008
dc.date2015-06-30T19:13:46Z
dc.date2015-11-26T14:39:42Z
dc.date2015-06-30T19:13:46Z
dc.date2015-11-26T14:39:42Z
dc.date.accessioned2018-03-28T21:45:32Z
dc.date.available2018-03-28T21:45:32Z
dc.identifier
dc.identifierRevista Brasileira De Hematologia E Hemoterapia. , v. 30, n. SUPPL. 1, p. 37 - 40, 2008.
dc.identifier15168484
dc.identifier10.1590/S1516-84842008000500010
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-55949113877&partnerID=40&md5=d1f6e12945484d5b9a136ee27a0c7b02
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/105334
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/105334
dc.identifier2-s2.0-55949113877
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1250104
dc.descriptionDespite the success with imatinib as the first choice treatment of chronic myeloid leukemia (CML), there is still a subset of patients that do not respond optimally to or are intolerant of this drug or lose response. Imatinib resistance can occur at any phase, but it is more frequent in advanced phases, with mutations in the BCRABL kinase domain being the most common mechanism of resistance. More potent tyrosine kinase inhibitors have been developed that can overcome resistance to imatinib. Nilotinib and dasatinib are good examples of new tyrosine kinase inhibitors that are available. With these new agents, patients who develop imatinib resistance or those unable to tolerate imatinib treatment can achieve significant clinical responses.
dc.description30
dc.descriptionSUPPL. 1
dc.description37
dc.description40
dc.descriptionJabbour E, Cortes J, Ghanem H, O'Brien, Kantarjian H. Target therapy in chronic myeloid leukemia. Expert Rev. Anticancer Ther. 2008;8(1):99-110Brave, M., Goodman, J., Kaminskas, E., Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistent to or intolerant of imatinib mesylate (2008) Clin Câncer Res, 14 (2), pp. 352-359
dc.descriptionDasatinib, K.S., In chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia (2008) Adis Drug Profile, 22 (1), pp. 59-69
dc.descriptionGolemovic, M., Verstovsek, S., Giles, F., AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia (2005) Clin Cancer Res, 11, pp. 4941-4947
dc.descriptionWeisberg, E., Manley, P.W., Breitenstein, W., Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl (2005) Cancer Cell, 7, pp. 129-141
dc.descriptionManley, P., Cowan-Jacob, S.W., Mestran, J., Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukemia (2005) Biochem Biophys Acta, 1754, pp. 3-13
dc.descriptionJabbour, E., Corets, J., O'Brien, S., Giles, F., Kantarjian, H., New targeted therapies for chronic myelogenous leukemia: Opportunities to overcome imatinib resistance (2007) Semin Hematol, 44 (SUPPL. 1), pp. S25-S31
dc.descriptionLe Coutre, P., Baskaynak, G., Tamm, I., Activity and induction of apoptosis of the specific tyrosine kinase inhibitor AMN 107 in bcr-abl+ cell lines and in imatinib resistant primary cells from CML patients (2004) Blood, 104, pp. 218a
dc.descriptionKantarjian, H.M., Giles, F., Gattermann, N., Bhalla, K., Alimena, G., Palandri, F., Nilotinib (formerly AMN107), a highly selective BCRABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance (2007) Blood, 110 (10), pp. 3540-3546
dc.descriptionG. Rosti, Le Coutre, K. Bhalla, F. Giles, G. Ossenkoppele, A. Hochhaus, et al. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 25, No.18S (June 20 Suplement) 2007: 7007Le Coutre, P., Ottmann, O.G., Giles, F., Kim, D.W., Cortes, J., Gattermann, N., (2007) Nilotinib (formerly AMN107), a highly selective BCRABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated phase chronic myelogenous leukemia, , Prepublished on line Dec, doi 10.1182-Blood-2007-04-830196
dc.descriptionOttmann OG, Kantarijian H, Larson, et al. A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph + acute lymphoblastic leukemia (ALL). Abstract. Paper presented at American Society of Hematology48th Annual Meeting
dc.descriptionDecember9-12, 2006
dc.descriptionOrlando, FlaHochhaus, A., Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure (2007) Expert Opinion, 8 (18), pp. 3257-3264
dc.descriptionHochhaus, A., Management of Bcr-Abl-positive leukemias with dasatinib (2007) Drug Profile, 7 (11), pp. 1529-1536
dc.languagept
dc.publisher
dc.relationRevista Brasileira de Hematologia e Hemoterapia
dc.rightsaberto
dc.sourceScopus
dc.titleThe Inhibitors Of Tyrosine Kinase [os Inibidores De Tirosino Quinase De Segunda Geração]
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución